Advances in the treatment of malignant Gliomas Journal Article

  


Authors: Khasraw, M.; Lassman, A. B.
Article Title: Advances in the treatment of malignant Gliomas
Abstract: Local control with surgery, radiation, and temozolomide chemotherapy remain the pillars of treatment for high-grade gliomas. Novel therapeutic strategies, including a variety of antiangiogenic agents, are under investigation. One of these agents, bevacizumab, was recently given accelerated approval by the US Food and Drug Administration as a single agent for recurrent glioblastoma. Recent trial results are generating important clinical questions regarding which patients to treat and when, and how best to monitor response. Encouraging results of recent studies are driving willingness to undertake aggressive treatment and to improve outcomes in this population. In this era, better understanding of biology, molecular aspects of cancer, and clinical trial methodology are crucial for clinicians. This review focuses on recent advances in the treatment malignant gliomas, especially antiangiogenic therapy. © 2010 Springer Science+Business Media, LLC.
Keywords: cancer survival; protein expression; treatment response; survival rate; unclassified drug; overall survival; clinical trial; disease course; drug tolerability; review; cancer recurrence; salvage therapy; bevacizumab; cancer combination chemotherapy; diarrhea; drug potentiation; gastrointestinal hemorrhage; hypertension; treatment duration; antineoplastic agents; drug approval; temozolomide; glioma; brain neoplasms; colorectal cancer; progression free survival; multiple cycle treatment; bone marrow suppression; vincristine; dna methylation; carmustine; lomustine; procarbazine; irinotecan; lung embolism; wound; myelodysplastic syndrome; cancer vaccine; glioblastoma; vaccination; antiangiogenic therapy; cediranib; vandetanib; carboxymethylcellulose polycytidylic polyinosinic acid polylysine; immunomodulation; methylated dna protein cysteine methyltransferase; digestive system perforation; cerebrovascular accident; cilengitide; kidney dysfunction; cdx 110 vaccine; talampanel
Journal Title: Current Oncology Reports
Volume: 12
Issue: 1
ISSN: 1523-3790
Publisher: Springer  
Date Published: 2010-01-01
Start Page: 26
End Page: 33
Language: English
DOI: 10.1007/s11912-009-0077-4
PUBMED: 20425605
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-76749157903&partnerID=40&md5=ccb0ebe9a495674e6bcd5a6a7c1179bd
Notes: --- - "Cited By (since 1996): 2" - "Export Date: 20 April 2011" - "CODEN: CORUA" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Andrew Lassman
    111 Lassman
  2. Mustafa Khasraw
    10 Khasraw
Related MSK Work